Evidence map›Paper›PMID 34391418›Full record

Trial reportRespiratory research2021

Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial.

Severin Vogt, Jörg D Leuppi, Philipp Schuetz, Beat Mueller, Carmen Volken, Sarah Dräger, Marten Trendelenburg, Jonas Rutishauser, Michael Osthoff

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Severin Vogt *Division of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Jörg D Leuppi *Department of Medicine, Kantonsspital Baselland, Liestal, Switzerland.
Philipp SchuetzMedical University Department, Kantonsspital Aarau, Aarau, Switzerland.
Beat MuellerMedical University Department, Kantonsspital Aarau, Aarau, Switzerland.
Carmen VolkenCentral Laboratory, Kantonsspital Baselland, Bruderholz, Switzerland.
Sarah DrägerDivision of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Marten TrendelenburgDivision of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Jonas Rutishauser *Faculty of Medicine, University of Basel, Basel, Switzerland.
Michael Osthoff *Division of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. Michael.Osthoff@usb.ch.ORCID http://orcid.org/0000-0001-5439-957X
University of Basel · CHKantonsspital Baselland · CHKantonsspital Baselland Standort Bruderholz · CHUniversity Hospital of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe innate and adaptive immune system is involved in the airway inflammation associated with acute exacerbations in patients with chronic obstructive pulmonary disease (COPD). We evaluated the association of mannose-binding lectin (MBL), immunoglobulin (Ig) and ficolin-2 concentrations with COPD exacerbations and according to the glucocorticoid treatment duration for an index exacerbation.

methodsPost-hoc analysis of the randomized, double-blind, placebo-controlled REDUCE trial of 5 vs. 14 days of glucocorticoid treatment for an index exacerbation. MBL, ficolin-2 and total IgG/IgA and subclass concentrations were determined in stored samples drawn (n = 178) 30 days after the index exacerbation and associated with the risk of re-exacerbation during a 180-day follow-up period.

resultsIgG and subclass concentrations were significantly lower after 14 days vs. 5 days of glucocorticoid treatment. Patients with higher MBL concentrations were more likely to suffer from a future exacerbation (multivariable hazard ratio 1.03 per 200 ng/ml increase (95% confidence interval (CI) 1.00-1.06), p = 0.048), whereas ficolin-2 and IgG deficiency were not associated. The risk was most pronounced in patients with high MBL concentrations, IgG deficiency and 14 days of glucocorticoid treatment pointing towards an interactive effect of MBL and IgG deficiency in the presence of prolonged glucocorticoid treatment duration [Relative excess risk due to interaction 2.13 (95% CI - 0.41-4.66, p = 0.10)]. IgG concentrations were significantly lower in patients with frequent re-exacerbations (IgG, 7.81 g/L vs. 9.53 g/L, p = 0.03).

conclusionsMBL modified the short-term exacerbation risk after a recent acute exacerbation of COPD, particularly in the setting of concurrent IgG deficiency and recent prolonged systemic glucocorticoid treatment. Ficolin-2 did not emerge as a predictor of a future exacerbation risk.

Indexed as

Disease ProgressionAdultAgedAged, 80 and overBiomarkersDouble-Blind MethodFemaleFicolinsFollow-Up StudiesForecastingHumansIgG DeficiencyImmunoglobulin GLectinsMaleMannose-Binding LectinBiomarkersFicolinsImmunoglobulin GLectinsMannose-Binding LectinMBL2 protein, humanChronic obstructive pulmonary diseaseExacerbationFicolin-2Glucocorticoid treatmentImmunoglobulinMannose-binding lectin

Identifiers

PMID34391418
PMCPMC8364051
OpenAlexW3195153072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.